GG 
Principal Investigator/Proqram Director (Last, First, middle) 
BIOGRAPHICAL SKETCH 
Give the following information for the key personnel and consultants and collaborators. Begin with the principal 
investigator/program director. Photocopy this page for each person. 
CVs 
NAME 
POSITION TITLE 
Alfred E. Chang, M.D. 
Professor of Surgery 
INSTITUTION AND LOCATION 
DEGREE 
YEAR 
CONFERRED 
FIELD OF STUDY 
Dartmouth College, Hanover, NH 
BA 
1971 
Chemistry 
Harvard Medical School, Boston, MA 
MD 
1974 
Medicine 
Duke University Medical Center, Durham, NC 
1974-1979 
Surg. Int/Res 
National Cancer Institute, Bethesda, MD 
1976-1979 
Surgical Oncology 
Hosp. Univ. of Penn., Philadelphia, PA 
1979-1982 
Surgery Resident 
RESEARCH AND/OR PROFESSIONAL EXPERIENCE: Concluding with present position, list in chronological order previous employment, experience, ana 
honors. Key personnel Include the principal Investigator and any other individuals who participate in the scientific development or execution of the project. Key 
personnel typically will include all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or 
baccalaureate level provided they contribute in a substantive way to the scientific development or execunon of the project. Include present membersnip on any 
Federal Government public advisory committee. List, in chronological order, the titles, all authors, and complete references to all publications during the past 
three years and to representative earlier publications pertinent to this applicaDon. DO NOT EXCEED TWO PAGES. 
Professional Experience: 
1982-1987 Senior Investigator, Surgery Branch, NCI, Bethesda, MD 
1984-1987 Asst.Prof.Surg. Uniformed Services of the Health Sciences, Bethesda, MD 
1988-Pres. Director, GI Tumor Program, Univ. of Mich. Cancer Center 
1988-Pres. Associate Director, Clinical Affairs, Univ. of Mich. Cancer Center 
1988-1992 Assoc. Prof., Surg., University of Michigan, Ann Arbor, MI 
1992-Pres. Professor of Surg., University of Michigan, Ann Arbor, MI 
1988-Pres. Chief, Div. of Surg. Oncology, Univ. of Mich., Ann Arbor, MI 
Academic Activities: 
Member, Editorial Board, Surgical Oncology, Member, Editorial Board, Annals of Surgical Oncology, 
Reviewer, American Cancer Society, Clinical Study Section, grants review program. 
Bibliography: (selected from list of 901 
1. Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg, SA: The systemic 
administration of purified interleukin-2 enhances the ability of sensitized murine lymphocytes to cure a 
disseminated syngeneic lymphoma. J Immunol 132:2123-2128, 1984. 
2. Chang AE, Lotze MT, Ames RS, Roth JA, Rosenberg SA: A large scale method of separating multiple 
lymphokines secreted by the murine EL-4 thymoma. J Immunopharm 7:17-31, 1985. 
3. Chang AE, Hyatt H, Rosenberg SA: Systemic administration of recombinant human interleukin-2 in 
mice. J Biol Resp Mod 3:561-572. 1984. 
4. Kaufmann Y, Chang AE, Robb RJ, Rosenberg SA: Mechanism of action of cyclosporin A; inhibition of 
lymphokine secredon studied with antigen-srimulated T cell hybridomas. J Immunol 133:31 07-3111. 
1984. 
5. Matory YL, Chang AE, Lipford N, Braziel R, Rosenberg SA: The toxicity of recombinant human IL-2 
in rats following IV infusion. J Biol Resp Mod 4:377-390 1985. 
6. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, 
Shiloni E, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of 
autologous lymphokine-acuvated killer cells and recombinant interleukin-2 to pauents with metastatic 
cancer. N Enel J Med 313:1485-1492. 1985. 
7. Chang AE, Shu S, Chou T, Lafreniere R, Rosenberg SA: Differences in the effects of host suppression 
on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res 46:3426-3430, 1986. 
8. Lotze MT, Chang AE, Seipp CA, Simpson RN, Vetto JT, Rosenberg SA: High dose recombinant 
interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related 
morbidity and histologic findings. JAMA 256:3117-3124, 1986. 
9. Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA: Reduction of toxicity of interleukin-2 and 
lymphokine activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5:496- 
503, 1987. 
10. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FD, Leitman S, Linehan WM, Robertson CN, 
Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: Clinical experience with the treatment of 157 
PHS 398 (Rev. 10/88) Page 9/8/93 4:27 PM 
* Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 5a, 5b. 
Recombinant DNA Research, Volume 18 
[811] 
